Another attempt to increase the efficacy of PDT was described by Bhuvaneswari et al. who used hypericin in combination with Erbitux (an angiogenesis inhibitor), which acts on the epidermal growth factor receptor (EGFR) in human bladder cancer cells. Here, EGFR is linked to urinary bladder cancer.